Entrada Therapeutics (TRDA) Current Assets (2020 - 2026)

Entrada Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $266.9 million for Q1 2026.

• In Q1 2026, Current Assets fell 33.81% year-over-year to $266.9 million; the TTM figure through Mar 2026 stood at $266.9 million (down 33.81% YoY), while the FY2025 annual figure was $306.3 million, down 30.4% from the prior year.
• Current Assets for Q1 2026 stood at $266.9 million, down from $306.3 million in the prior quarter.
• The five-year high for Current Assets was $489.5 million in Q2 2024, with the low at $209.9 million in Q4 2022.
• The 5-year median for Current Assets is $369.8 million (2023), against an average of $355.4 million.
• The sharpest annual moves came in 2022 and 2026: Current Assets soared 90.03% in 2022, then tumbled 33.81% in 2026.
• Entrada Therapeutics' Current Assets stood at $209.9 million in 2022, then surged by 76.19% to $369.8 million in 2023, then increased by 19.0% to $440.0 million in 2024, then plunged by 30.4% to $306.3 million in 2025, then decreased by 12.86% to $266.9 million in 2026.
• Business Quant data shows TRDA's Current Assets at $266.9 million in Q1 2026, $306.3 million in Q4 2025, and $338.3 million in Q3 2025.